SCHEMBL20503855

SCHEMBL20503855

O=c1cc(-c2cn(COP(=O)(OCn3cc(-c4ccn(Cc5cc(F)cc(Br)c5)c(=O)c4)c4cc(N5CCOCC5)cnc43)OCn3cc(-c4ccn(Cc5cc(F)cc(Br)c5)c(=O)c4)c4cc(N5CCOCC5)cnc43)c3ncc(N4CCOCC4)cc23)ccn1Cc1cc(F)cc(Br)c1

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 18/20 0.46
▸ STAT6 P42226 1/20 0.38
▸ CHEK1 O14757 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25973959 0.95 MAPK1 (0.43) MAPK1STAT6CHEK1
SCHEMBL20503858 0.94 MAPK1 (0.45) MAPK1STAT6CHEK1
SCHEMBL21557749 0.94 MAPK1 (0.44) MAPK1STAT6CHEK1
SCHEMBL30497095 0.94 MAPK1 (0.44) MAPK1STAT6CHEK1
SCHEMBL20503951 0.91 MAPK1 (0.49) MAPK1STAT6CHEK1
SCHEMBL20503878 0.91 MAPK1 (0.49) MAPK1
SCHEMBL20503867 0.90 MAPK1 (0.51) MAPK1
SCHEMBL25970919 0.89 MAPK1 (0.49) MAPK1STAT6
SCHEMBL21541547 0.87 MAPK1 (0.49) MAPK1STAT6CHEK1
SCHEMBL21557921 0.87 MAPK1 (0.49) MAPK1STAT6CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10995089-B2 Zaindole derivatives and their use as ERK kinase inhibitors AGV DISCOVERY (FR) 2021-05-04 — — US claimed
EP-3377491-B1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2019-11-13 — — EP claimed
EP-3377491-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV Discovery (FR) 2018-09-26 — — EP claimed
US-11708364-B2 Azaindole derivatives and their use as ERK kinase inhibitors AGV DISCOVERY (FR) 2023-07-25 — — US disclosed
US-20210221809-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV Discovery ENSCM (FR) 2021-07-22 — — US disclosed
EP-3377491-B1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2019-11-13 — — EP disclosed
EP-3377491-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV Discovery (FR) 2018-09-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10995089-B2 Zaindole derivatives and their use as ERK kinase inhibitors MAPKAPK2, MAPK1, MAPK3 MAPK1 2/4885STAT6 527/4885CHEK1 621/4885
US-11708364-B2 Azaindole derivatives and their use as ERK kinase inhibitors MAPKAPK2, MAPK1, MAPK3 MAPK1 2/4885STAT6 697/4885CHEK1 473/4885
US-20210221809-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS MAPKAPK2, MAPK1, MAPK3 MAPK1 2/4885STAT6 697/4885CHEK1 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback